NOTCH1 activation in breast cancer confers sensitivity to inhibition of SUMOylation - Université de Montpellier Accéder directement au contenu
Article Dans Une Revue Oncogene Année : 2015

NOTCH1 activation in breast cancer confers sensitivity to inhibition of SUMOylation

Résumé

Breast cancer is genetically heterogeneous, and recent studies have underlined a prominent contribution of epigenetics to the development of this disease. To uncover new synthetic lethalities with known breast cancer oncogenes, we screened an epigenome-focused short hairpin RNA library on a panel of engineered breast epithelial cell lines. Here we report a selective interaction between the NOTCH1 signaling pathway and the SUMOylation cascade. Knockdown of the E2-conjugating enzyme UBC9 (UBE2I) as well as inhibition of the E1-activating complex SAE1/UBA2 using ginkgolic acid impairs the growth of NOTCH1-activated breast epithelial cells. We show that upon inhibition of SUMOylation NOTCH1-activated cells proceed slower through the cell cycle and ultimately enter apoptosis. Mechanistically, activation of NOTCH1 signaling depletes the pool of unconjugated small ubiquitin-like modifier 1 (SUMO1) and SUMO2/3 leading to increased sensitivity to perturbation of the SUMOylation cascade. Depletion of unconjugated SUMO correlates with sensitivity to inhibition of SUMOylation also in patient-derived breast cancer cell lines with constitutive NOTCH pathway activation. Our investigation suggests that SUMOylation cascade inhibitors should be further explored as targeted treatment for NOTCH-driven breast cancer.

Domaines

Cancer

Dates et versions

hal-02287227 , version 1 (13-09-2019)

Identifiants

Citer

M Licciardello, M Müllner, G Dürnberger, C Kerzendorfer, B Boidol, et al.. NOTCH1 activation in breast cancer confers sensitivity to inhibition of SUMOylation. Oncogene, 2015, 34 (29), pp.3780-3790. ⟨10.1038/onc.2014.319⟩. ⟨hal-02287227⟩
24 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More